Hadasit Bio-Holdings

Press Releases

Expiration of the Option of Teva Under the License Agreement with CellCure Neurosciences

Feb. 16, 2015

HBL – Hadasit Bio-Holdings Ltd.

(the “Company”)

February 16, 2015

 

 

To                                            To

Securities Authority                Tel Aviv Stock Exchange Ltd.

www.isa.gov.il                        www.tase.co.il

 

 

Re: Expiration of the Option of Teva Under the License Agreement with CellCure Neurosciences

 

Further to the immediate reports of the Company dated October 10, 2010, January 1, 2015 and January 31, 2015 (reference nos.: 2010-01-640794, 2015-01-000100 and 2015-01-021730, respectively), regarding the signature of the license agreement between CellCure Neurosciences Ltd., a company of which 21.2% is held by the Company (hereinafter: “CellCure”) and Teva Pharmaceutical Industries Ltd. (hereinafter: “Teva”), whereby CellCure granted Teva an option to receive a general and exclusive worldwide license to develop and commercialize CellCure’s OpRegen product (hereinafter: the “License”) for the treatment of patients with dry age-related macular degeneration (hereinafter: the “Option”) by February 15, 2015, the Company hereby announced that the Option period has ended and the Option granted to Teva has expired.

In light of the expiration of the Option as stated, CellCure may conduct negotiations with third parties as of the date of this immediate report.

 

 

 

Sincerely,

 

HBL – Hadasit Bio-Holdings Ltd.

By: Ms. Tamar Kfir, CEO

                                                                                    

 
 

Press Releases Archive